|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||17.95 - 18.08|
|52 Week Range||17.95 - 18.08|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Rockville-based Sucampo Pharmaceuticals Inc. has officially been sold to U.K. pharmaceutical giant Mallinckrodt PLC. The $1.2 billion deal, including debt, closed Tuesday after Sucampo (SCMP) shareholders tendered a total 39.16 million shares, or 86 percent of all outstanding shares, in favor of the deal by 8 a.m. That satisfied the minimum requirements for the purchase to be consummated — more than 50 percent of Sucampo's shares in support — so it didn't need to move to a stockholder vote. As a result, Sucampo shares stopped trading Tuesday on the Nasdaq exchange, and the company now stands as a wholly owned subsidiary of Mallinckrodt (MNK).
Mallinckrodt PLC (NYSE: MNK ) agreed to buy Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP ) in a deal announced in December. The Analyst Weighing in the planned acquisition, Barclays analyst Douglas Tsao ...
The FDA accepts the new drug application for Theravance (TBPH) and partner Mylan's COPD candidate, revefenacin. A response on the same is expected on Nov 13, 2018.
Moody's Investors Service ("Moody's") confirmed Mallinckrodt International Finance SA's ("Mallinckrodt") Corporate Family Rating ("CFR") at Ba3 and Probability of Default ...
The Committee for Medicinal Products for Human Use passes a positive viewpoint on Glaxo's (GSK) shingles vaccine, Shingrix. A final decision from the EU is awaited in April 2018.
Dr. Reddy's (RDY) earnings per American Depositary Share were down 27.3% in third-quarter fiscal 2018 from the year-ago quarter while the top line beat the prior-year figure.
Shire (SHPG) receives an FDA approval for transferring the product manufacturing technology of its hereditary angioedema drug, Cinryze, to its manufacturing site in Vienna, Austria.
Anthera (ANTH) posts positive results from the second interim futility analysis of Sollpura for EPI. Top-line data from the study is expected in the first quarter of 2018.
Last year's FDA approval of Agios' (AGIO) only marketed drug Idhifa and its rapid progress on a robust pipeline during the period drive the share price consistently.
Regulatory approvals of some key pipeline candidates along with the strong performance of products like Victoza have contributed to a rally in Novo Nordisk's (NVO) shares.
Endo International (ENDP) lost 35% in the past year mired by controversy related to Opana ER and weaknesses in both the businesses.
The FDA panel votes against the approval of Aradigm's (ARDM) Linhaliq for treatment of non-cystic fibrosis bronchiectasis. A response from the regulatory agency is expected on Jan 26, 2018.
Endo (ENDP) announced that it received a subpoena from the Florida authorities in connection with products related to opioid misuse.
Adamas (ADMS) shares climb on the commercial launch of Gocovri in the United States for treating dyskinesia in patients with Parkinson's disease. This is the first FDA approved drug for the ailment.
Acorda (ACOR) announces preliminary sales numbers of its key multiple sclerosis drug, Ampyra, for Q4. The company's net sales expectations are higher year over year.
Mallinckrodt's (MNK) strategy to streamline its business to evolve as a top-performing specialty pharmaceutical company has led the company to enter into an agreement to sell Recothrom and Preveleak to Baxter.
Chris and Hugh Hempel, parents of twin girls with an extremely rare and fatal genetic disease, are suing the rare disease therapy accelerator Cydan and the biotech companies Vtesse and Sucampo Pharmaceuticals for alleged breach of contract, unjust enrichment, and misappropriation of trade secrets.
Emergent (EBS) initiates a phase II dose-ranging trial to evaluate the safety, pharmacokinetics and clinical benefit of its investigational FLU-IGIV to treat influenza virus infection.
Celsion's (CLSN) plan for phase I/II study to evaluate DNA-based immunotherapy, GEN-1, in ovarian cancer gets FDA approval and clearance for initiation.
Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.